GSK Touts Alli As Tip Of OTC Strength, Reaffirms Consumer Commitment
This article was originally published in The Tan Sheet
Executive Summary
Sales exceeding $150 million in two weeks on retail shelves for OTC weight-loss drug alli figure prominently in GlaxoSmithKline's commitment to its consumer health care products division, senior executives say
You may also be interested in...
GSK Invests In Consumer Unit To Overcome Generic Threat, Low Alli Sales
GlaxoSmithKline expects to overcome increasing generic competition by growing its consumer health business and investing in emerging markets, rather than by pursuing a mega-merger like Pfizer-Wyeth
Alli Sales Slender On Lower Retailer Demand, Flatten GSK Consumer Sales
Significantly lower sales of GlaxoSmithKline's alli OTC weight-loss drug combined with struggles in the nicotine replacement therapy category weighed down the consumer health care division's performance in the firm's latest quarter
Alli Sales Top 2 Million Starter Packs, Drive GSK’s OTC Sales
GlaxoSmithKline's over-the-counter product sales posted a 24 percent increase to $854.6 million for the third quarter, driven in by U.S. sales of its alli weight loss drug, the firm said in an Oct. 24 earnings call